ArticleBMC cancer2025
Erythrocyte lifespan for predicting moderate and severe anemia in advanced gastric cancer patients post-anti-tumor therapeutics: a prospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAnti-tumor Therapeutics often cause anemia in advanced gastric cancer (AGC) patients. Currently, anemia is often diagnosed based on hemoglobin levels, but these tests are reactive rather than predictive. Erythrocyte lifespan (ELS) a crucial physiological parameter, yet its relationship with anemia after anti-tumor treatment in AGC patients remains unclear. We aimed to investigate the potential of ELS in predicting the development of moderate and severe anemia in patients with AGC following anti-tumor therapeutics.
methods56 AGC patients meeting specific criteria were enrolled from Oct 2023 to Oct 2024. ELS was determined with the Levitt's CO breath test-a non-invasive, bedside procedure. Correlations between ELS and various parameters were analyzed, t-tests were applied to analyze differences. The ROC curve was utilized to evaluate the predictive ability of ELS. Data analyzed via GraphPad Prism 9.0.0.
resultsELS was significantly positively correlated with hemoglobin, age, hematocrit, and mean corpuscular hemoglobin concentration, and negatively correlated with bilirubin. Patients with ELS less than 70 days had lower hemoglobin levels. The area under the ROC curve for ELS in predicting moderate and severe anemia 7-21 days after treatment was 0.8946, with an optimal cut-off value of 72.5 days.
conclusionFor the first time, we demonstrate that baseline ELS can reliably forecast moderate-to-severe anemia 7-21 days after anti-tumor therapy in AGC advanced gastric cancer patients. This prospective proof-of-concept shifts anemia management from reactive hemoglobin monitoring to proactive risk stratification, enabling timely initiation of erythropoiesis-stimulating agents or iron supplementation and potentially reducing treatment interruptions.
trial registrationThis trial was retrospectively registered at China Clinical Trials Registry (ChiCTR2500097950) on February 27, 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.